While most of the 30 stocks that comprise BioWorld’s Drug Developers Index (BDDI) are trading down for the year, the three showing the most upward movement in 2021 include a company at the forefront of COVID-19 vaccine development, an RNAi therapeutics firm that became a multibillion-dollar acquisition target, and a neurological disease company with one marketed product. Read More
Combining the metabolites glutamine or inosine with ampicillin (AMP) could represent a new therapeutic approach to antimicrobial resistance that also avoids the development of acquired resistance to next-generation antibiotics, according to a new Chinese study led by scientists at Sun Yat-sen University (SYSU) in Guangzhou. Read More
Preliminary data from a phase IIIb study of Johnson & Johnson’s Ad26.COV2.S COVID-19 vaccine showed a homologous booster dose was 85% effective against hospitalization in participants from South Africa. Read More
PERTH, Australia – Australia should be at the front of the line among developed nations when it comes to innovative drugs and devices, but health policies must evolve to respond to changes in technology and global trends, Johnson & Johnson (J&J) said. Although Australia’s health policy has served the country well, tensions in the system are becoming seismic shifts that mirror international trends, J&J said in a recent report on Australia’s health system. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Antengene, Bharat, Jazz, Madrigal, Ocugen. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Beximco, Blueprint, Enbiotix, Lengo, Pfizer, Polyphor. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Immunovant. Read More
